Everolimus and Tumor marker increased - a phase IV clinical study of FDA data

Summary:

Tumor marker increased is reported as a side effect among people who take Everolimus (everolimus), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Palbociclib, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Tumor marker increased when taking Everolimus. It is created by eHealthMe based on reports of 16,218 people who have side effects when taking Everolimus from the FDA, and is updated regularly.

What is Everolimus?

Everolimus has active ingredients of everolimus. eHealthMe is studying from 16,228 Everolimus users. Check the latest studies of Everolimus.

What is Tumor marker increased?

Tumor marker increased is found to be associated with 352 drugs and 388 conditions by eHealthMe. Check the latest studies of Tumor marker increased.

On May, 11, 2026

16,218 people reported to have side effects when taking Everolimus.
Among them, 72 people (0.44%) have Tumor marker increased.

Could Everolimus cause Tumor marker increased?

Among these 72 people:

How long have people been on Everolimus when they have Tumor marker increased? *

What is the gender of people who have Tumor marker increased when taking Everolimus? *

female: 95.31 %
male: 4.69 %

What is the age of people who have Tumor marker increased when taking Everolimus? *

What are other drugs people take besides Everolimus? *

What are other side effects people have besides Tumor marker increased? *

Malignant Neoplasm Progression (cancer tumour came back): 35 people, 48.61%
Metastases To Bone (cancer spreads to bone): 19 people, 26.39%
Metastases To Lung (cancer spreads to lung): 14 people, 19.44%
Breast Cancer Metastatic: 14 people, 19.44%
Metastases To Liver (cancer spreads to liver): 13 people, 18.06%
Pain: 12 people, 16.67%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 12 people, 16.67%
Renal Impairment (severely reduced kidney function): 11 people, 15.28%
Blood Glucose Abnormal: 11 people, 15.28%
Skin Toxicity (skin damage due to toxin/poison): 10 people, 13.89%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 35 people, 48.61%
Breast Cancer: 24 people, 33.33%
Metastases To Bone (cancer spreads to bone): 10 people, 13.89%
Endometrial Cancer Metastatic: 8 people, 11.11%
Breast Cancer Recurrent: 6 people, 8.33%
Carcinoid Tumor: 3 people, 4.17%
Laxative Supportive Care: 2 people, 2.78%
Disease Progression: 2 people, 2.78%
Sleep Disorder: 2 people, 2.78%
Nausea (feeling of having an urge to vomit): 2 people, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Everolimus and have Tumor marker increased?

- Check whether Tumor marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Everolimus:

Everolimus (16,228 reports)

Browse all side effects of Everolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor marker increased:

Tumor marker increased (352 drugs)

Browse all the conditions that are associated with Tumor marker increased:

Tumor marker increased (388 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Everolimus) and Everolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.